FI
Fischer Medical Ventures Ltd (FISCHER)
₹22.33
Mkt cap
₹1,560 Cr
P/E ratio
137.00
P/B
3.35
Div yield
0.22%
ROE
8.91%
ROCE
11.40%
EPS (TTM)
₹0.16
Book value
₹7
52W range
22–53
Sector
Healthcare
Price history
Previous close
Fischer Medical Ventures Ltd, earlier known as Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides AI-based health screening and digital-health solutions. Its MRI manufacturing plant is located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam. [1]
NSE FISCHERBSE 524743
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsBearish
52-week range
−57.76% from high₹22
₹22+2.53% from low₹53
Current
₹22.33
Prev close
₹22.86
Day
−2.32%
Price performance
1D
−2.01%
1W
−9.93%
1M
−6.16%
3M
−42.49%
6M
−35.56%
1Y
−61.87%
YTD
−46.62%
Financials
Revenue, profit & margin
P/E ratio
137.0×
FISCHER is 271% above the sector median of 36.9×
FISCHER137.0×
Sector median36.9×
| Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 20.79 | 10.12 | 39.66 | 11.75 | 49.17 | 23.44 | 86.30 | 101.10 | 97.54 | 81.92 | 107.44 | |
| YoY Sales growth | +136.51% | +131.62% | +117.60% | +760.43% | +98.37% | +249.49% | +24.50% | ||||||
| Expenses | 0.00 | 18.28 | 10.33 | 39.16 | 11.38 | 46.66 | 19.45 | 70.13 | 79.53 | 101.31 | 70.67 | 98.50 | |
| Operating Profit | 0.00 | 2.51 | -0.21 | 0.50 | 0.37 | 2.51 | 3.99 | 16.17 | 21.57 | -3.77 | 11.25 | 8.94 | |
| OPM % | 12.07% | -2.08% | 1.26% | 3.15% | 5.10% | 17.02% | 18.74% | 21.34% | -3.87% | 13.73% | 8.32% | ||
| Other Income | 0.00 | 0.47 | 0.69 | 0.05 | 0.38 | 0.15 | 7.47 | 2.48 | 1.09 | 0.77 | 1.48 | 4.58 | |
| Interest | 0.00 | 0.05 | 0.13 | 0.05 | 0.07 | 0.23 | 0.66 | 0.92 | 0.64 | 3.66 | 3.54 | 3.43 | |
| Depreciation | 0.00 | 0.18 | 0.28 | 0.29 | 0.56 | 0.51 | 0.77 | 0.51 | 0.77 | 0.93 | 1.36 | 1.34 | |
| Profit before tax | 0.00 | 2.75 | 0.07 | 0.21 | 0.12 | 1.92 | 10.03 | 17.22 | 21.25 | -7.59 | 7.83 | 8.75 | |
| Tax % | 6.18% | 271.43% | -38.10% | 350.00% | 26.04% | 51.55% | 19.51% | 9.18% | 64.03% | 51.60% | 90.86% | ||
| Net Profit | 0.00 | 2.59 | -0.12 | 0.29 | -0.29 | 1.31 | 4.86 | 13.85 | 19.23 | -12.44 | 3.79 | 0.80 | |
| EPS in Rs | 0.00 | 0.05 | -0.00 | 0.01 | -0.01 | 0.02 | 0.07 | 0.21 | 0.30 | -0.19 | 0.06 | 0.01 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −3.55% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | −3.55% |
| +1 day | −1.32% |
| +5 days | −5.62% |
| +15 days | −7.56% |
| +30 days | −12.84% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202663.09%Promoter
Promoters63.09%0.94
FIIs6.71%1.23
DIIs1.26%0.09
Public28.95%2.06
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnosti | ₹1,495.50 | 237.68 | 17,234 | 0.00% | 8 | −86.23% | 259 | −55.36% | 18.48% |
| Poly Medicure | ₹1,635.70 | 52.46 | 16,580 | 0.21% | 95 | −4.31% | 581 | +30.79% | 12.50% |
| Sahajanand Medi | ₹527.60 | 74.68 | 5,363 | 0.00% | 26 | +32.12% | 373 | +24.69% | 11.35% |
| Tarsons Products | ₹303.40 | 197.34 | 1,614 | 0.00% | 0 | −110.24% | 124 | +20.83% | 4.59% |
| Fischer Medical | ₹22.33 | 137.10 | 1,560 | 0.22% | 1 | −94.22% | 107 | +24.50% | 11.45% |
| Laxmi Dental | ₹187.57 | 28.45 | 1,032 | 0.00% | 10 | +17.58% | 80 | +10.03% | 15.05% |
| Q-Line Biotech | ₹396.80 | 16.91 | 926 | 0.00% | 20 | −8.07% | 152 | +5.83% | 22.45% |
| Median: 18 Co. | ₹302.90 | 36.92 | 664 | 0.00% | 5 | −6.19% | 83 | +17.91% | 15.05% |
Filings
Annual reports15
Concall transcripts5
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 17 NovBoard Meeting Outcome for Approval Of Financial Results For The Quarter And Half Year Ended 30Th Sept 2026 14 Nov - Board approved Q2 FY27 results and allotment of 4.42 crore shares on warrant conversion worth ₹77.52 crore.Financial Results For Q2 FY26-27 14 Nov - On 14 Nov 2026, board approved Q2 FY27 results and allotted 4.417 crore shares via warrant conversion for ₹77.5 crore.Announcement under Regulation 30 (LODR)-Monitoring Agency Report 14 Nov - Monitoring agency report for quarter ended September 30, 2026 shows nil deviation in preferential issue proceeds.Board Meeting Intimation for Approval Of Q2 Financial Results And Other Allied Matters. 11 Nov - Board meeting on 14 Nov 2026 to consider Q2 and half-year FY2026 financial results.
